Evidence map›Paper›PMID 35070891›Full record

ArticleGland surgery2021

MicroRNA-30d target TIMP3 induces pituitary tumor cell growth and invasion.

Bowen Sun, Congxin Dai, Shangfeng Zhao, Hao Dong, Haocheng Liu, Yong Li, Renzhi Wang, Jun Kang

Open access · diamondAbstract read
In one paragraph

Article in Gland surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Bowen SunDepartment of Neurosurgery, Affiliated Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Congxin DaiDepartment of Neurosurgery, Affiliated Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Shangfeng ZhaoDepartment of Neurosurgery, Affiliated Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Hao DongDepartment of Neurosurgery, Affiliated Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Haocheng LiuDepartment of Neurosurgery, Affiliated Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Yong LiDepartment of Neurosurgery, Affiliated Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Renzhi WangDepartment of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Jun KangDepartment of Neurosurgery, Affiliated Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CNBeijing Tongren Hospital · CNPeking Union Medical College Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs one of the most common intracranial tumors, pituitary adenomas, especially the Cushing's disease subtype, have been studied for many years. However, at present, effective methods for the early diagnosis of pituitary adenomas are very limited, especially for subtypes such as Cushing's disease. Therefore, it is of urgent importance to find effective molecular targets to develop new diagnostic and therapeutic methods for pituitary adenomas.

methodsWe showed the abnormally high expression of miR-30d in pituitary adenomas by analyzing data in the Gene Expression Omnibus (GEO) database and revealed a novel molecular mechanism of miR-30d in regulating the proliferation and invasion of a pituitary adenoma cell line (AtT-20). Cell culture and transfection, and RNA interference (RNAi) were used to treat AtT-20 cells to test the effects of miR-30d and TIMP3 on cells. Quantitative polymerase chain reaction (qPCR) was used to determine the messenger RNA (mRNA) expressions. We used 3-(4,5-diphenyltetrazolium bromide) (MTT) to determine cell viabilities. An invasion assay was performed using Transwell chambers. Luciferase activity was tested with a dual-luciferase assay.

resultsWe found that the expression of miR-30d in pituitary adenoma was higher than that in normal pituitary tissues. It was revealed that miR-30d promoted the proliferation and invasion of AtT-20 cells by inhibiting the expression of TIMP3. In the above process, miR-30d could bind to the 3'-untranslated region (3'-UTR) of TIMP3 mRNA.

conclusionsThe mir-30d/TIMP3 signaling pathway plays an important regulatory role in pituitary adenomas. These new discoveries may reveal more functions of miR-30d and lay the foundation for future clinical development of new drug targets.

Indexed as

invasionmiR-30dpituitary adenomaTIMP3

Identifiers

PMID35070891
PMCPMC8749101
OpenAlexW4206476799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.